Imagenetix Receives FDA Clearance to Begin Pre-IND Safety Studies on Anti-Inflammatory Compound »
December 11, 2006
1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions...
Imagenetix Launches Retail Branding Program; Former Pharmavite Executives To Spearhead Campaign »
August 21, 2006
The first products to be branded under the program will be the company's Celadrin-based joint health formulas...
Imagenetix Appoints Former FDA, NIH Staffer to Guide IND Submission for Anti-Inflammatory Compound »
June 26, 2006
Imagenetix has engaged the services of Michael Hamrell, Ph.D., president of MORIAH Consultants, a regulatory affairs and clinical research consulting firm near Los Angeles...
Imagenetix Announces Positive Safety Studies on Anti-Inflammatory Compound, 1-TDC »
June 1, 2006
1-tetradecanol complex (1-TDC) has achieved expected results in important baseline acute toxicity studies...
Imagenetix Announces 1-Tetradecanol Complex Acts to Inhibit Bacteria and Enzymes Associated with Oral Disease, Sepsis and Inflammation »
May 8, 2006
1-TDC significantly inhibited the growth of Actinomyces viscosus, a microbe that has been shown to play a major role in oral microbial ecosystems...
Imagenetix Commissions New Study to Evaluate Celadrin® Capsules for Patients with Knee Osteoarthritis »
March 20, 2006
The primary purpose of this study is to confirm the positive clinical results, published in 2002 in the internationally acclaimed peer-reviewed Journal of Rheumatology...